Literature DB >> 1737106

Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): implications for the role of N-ras mutation in AML pathogenesis.

A Bashey1, R Gill, S Levi, C J Farr, R Clutterbuck, J L Millar, I B Pragnell, C J Marshall.   

Abstract

The number of steps involved in the pathogenesis of acute myeloid leukemia (AML) is unclear. The initiating event would be expected to exist in all leukemic cells, but subsequent events may be subclonal. If several genetic events occur, they may cooperate within the same cell or be alternatively acquired by different subclones. These possibilities cannot be adequately analyzed in DNA prepared directly from patient specimens. In this study, N-ras mutations demonstrable in DNA prepared from peripheral blood of 10 patients with AML were examined in primary in vitro colonies (AML-colony-forming units [CFU]) grown from these patients. Both colonies containing the mutant gene and colonies containing normal allele only were obtained from each patient. The proportion of colonies containing no mutant allele varied among patients (5% to 57%). A subset of mutation containing colonies appeared to have lost the normal allele in nine of 10 AML cases analyzed. In the four cases with two N-ras mutations, the two mutations were found to exist in different subclones. In these cases, macroscopic colonies (AML-MCFU) were also obtained using an assay system designed to select for earlier clonogenic cells than in the AML-CFU assay. The N12cys mutation in AML10 was found in the CFU, but not in the MCFU, and the N12asp mutation in AML43 was found in the MCFU, but not in the CFU. These results suggest that N-ras mutation is a postinitiation event in AML that contributes to the outgrowth of more malignant subclones. Where two mutations are found in a case of AML, they appear to have been acquired by separate subclones, which may show different degrees of differentiation.

Entities:  

Mesh:

Year:  1992        PMID: 1737106

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Authors:  Qing Li; Kevin M Haigis; Andrew McDaniel; Emily Harding-Theobald; Scott C Kogan; Keiko Akagi; Jasmine C Y Wong; Benjamin S Braun; Linda Wolff; Tyler Jacks; Kevin Shannon
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

2.  Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition.

Authors:  Craig Dorrell; Katsuto Takenaka; Mark D Minden; Robert G Hawley; John E Dick
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

3.  Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia.

Authors:  Mi-Jung Park; Soon-Ho Park; Pil-Whan Park; Yiel-Hea Seo; Kyung-Hee Kim; Ji-Hun Jeong; Moon Jin Kim; Jeong-Yeal Ahn; Jae Hoon Lee; Jinny Park; Junshik Hong
Journal:  Int J Hematol       Date:  2013-10-09       Impact factor: 2.490

4.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Authors:  Benjamin S Braun; David A Tuveson; Namie Kong; Doan T Le; Scott C Kogan; Jacob Rozmus; Michelle M Le Beau; Tyler E Jacks; Kevin M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

5.  The Notch pathway in ovarian carcinomas and adenomas.

Authors:  O Hopfer; D Zwahlen; M F Fey; S Aebi
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

6.  The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.

Authors:  B C Millar; J B Bell; R Barfoot; M Everard
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

7.  Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.

Authors:  Yang Shen; Ya-Kai Fu; Yong-Mei Zhu; Yin-Jun Lou; Zhao-Hui Gu; Jing-Yi Shi; Bing Chen; Chao Chen; Hong-Hu Zhu; Jiong Hu; Wei-Li Zhao; Jian-Qing Mi; Li Chen; Hong-Ming Zhu; Zhi-Xiang Shen; Jie Jin; Zhen-Yi Wang; Jun-Min Li; Zhu Chen; Sai-Juan Chen
Journal:  EBioMedicine       Date:  2015-04-12       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.